Sarcoidosis
ICD-10 D86 · ICD-11 4B20

Treatment of Sarcoidosis with Neurosarcoidosis: Mild to Moderately Disabling Disease

When sarcoidosis involves the nervous system — neurosarcoidosis — it can present across a spectrum of severity. This protocol addresses the mild to moderately disabling end of that spectrum, where neurological involvement is present but not immediately life-threatening.

Clinical Scenario

This protocol applies to patients with sarcoidosis and neurosarcoidosis presenting with mild to moderately disabling manifestations, which may include:

  • Cranial neuropathies (cranial nerves II and VIII)
  • Meningeal mass lesions
  • Hydrocephalus
  • CNS parenchymal disease
  • Peripheral neuropathies
  • Generalized myopathies

Treatment Approach & Goals

Management in this setting centres on oral corticosteroid therapy, with the treatment course guided by clinical response over the first month. The target is demonstrable clinical improvement within one month of initiating treatment.

The complete regimen — including dosing, taper schedule, and maintenance considerations — is available in the full structured protocol.
Instant Access to Structured Evidence-Based Regimens

References

  1. It is suggested that patients with mild to moderately disabling disease (cranial nerves II and VIII, meningeal mass lesions, hydrocephalus, CNS parenchymal disease, neuropathies and generalized myopathies) be treated with 20-30 mg prednisone daily for at least one month.
  2. If the patient improves, the dose can be decreased by 5 mg every two weeks as the clinical course is monitored.
  3. Patients may require a maintenance dose of 10 mg or lower daily even if they are treated with adjuvant drugs.
View source ↗